Physiomics shares rose on Wednesday after it announced it has secured multiple new and follow-on contracts worth more than £345,000 in total.
The awards come shortly after a shakeup of the board that investors will hope breathes fresh life into the firm.
The AIM-listed company, which supports drug developers with mathematical modelling, biostatistics and data science, said the awards secured so far this month span a mix of new and follow-on work with UK and international clients. Among them are a NASDAQ-listed clinical-stage biotech, several clinical-stage therapeutics developers and a number of leading cancer research groups.
The projects will draw on Physiomics’ expertise across modelling and simulation, biometrics and data science to support key stages of drug development, including Phase 1 and 2 clinical data analysis, first-in-human dose selection and ongoing clinical programme support.
Encouragingly for investors, several are expected to start imminently and will deliver revenue through to the end of 2027, giving the company both near-term income and useful medium-term visibility.
The board reckons the awards also underline the deepening quality of its client relationships, with repeat business pointing to a strengthening reputation as a trusted scientific partner across the biotech and pharma sectors.
Dr Peter Sargent, CEO of Physiomics, commented: “We are delighted to have secured these contract awards. They reflect our continued investment in business development and marketing, as well as the team’s success in expanding and diversifying our pipeline. These opportunities further strengthen our order book and improve revenue visibility across the business. Our broader pipeline remains strong and we’re excited about a number of additional opportunities that we hope to be able to announce soon”.